Tag: cardiac resynchronisation therapy
ESC 2026: targeted lead placement is no better than standard placement...
Targeted placement of a left ventricular lead does not improve outcomes in patients with heart failure undergoing cardiac resynchronisation therapy (CRT), according to results presented...
Randomised study demonstrates non-inferiority of two-lead alternative versus conventional CRT-D systems
Results from the multicentre CRT‑NEXT study have shown that CRT‑DX (Biotronik)—a two-lead cardiac resynchronisation therapy defibrillator (CRT-D) system—is as safe and effective as conventional...
US FDA approves “world’s first and only” leadless LVEP device for...
EBR Systems has received US Food and Drug Administration (FDA) approval of the WiSE system—marking what the company describes as a significant leap forward...
Adaptive CRT associated with decreased risk of AF compared to standard...
In a large, real-world population of cardiac resynchronisation therapy recipients followed by remote monitoring, use of the adaptive cardiac resynchronisation therapy biventricular and left...
Improving cardiac resynchronisation therapy
Jagmeet Singh is the founding director of the Resynchronisation and Advanced Cardiac Therapeutics Program. Singh is the principal investigator for the Personalised CRT-MPP Post-Approval...
Experts discuss non-responders to cardiac resynchronisation therapy at ESC scientific symposium
EPIC Alliance experts at the 2016 European Society of Cardiology (ESC; Rome, Italy) congress presented original research and real-world clinical evidence on non-responders to...